Salvage therapy with ritonavir-boosted amprenavir/fosamprenavir: Virological and immunological response in two years follow-up

HIV Clinical Trials

Volumn 6, Issue 2, 2005, Pages 73-80

  Quercia, Romina ^a   Garnier, Elisabeth ^a   Ferré, Virginie ^a   Morineau, Pascale ^a   Bonnet, Bénédicte ^a   Soulard, Claire ^a   Raffi, François ^a  

^a HÔTEL DIEU   (France)

Author keywords

Amprenavir; Fosamprenvavir; HIV; Salvage therapy

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ALGORITHM; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LONG TERM CARE; LYMPHOCYTE COUNT; MENTAL DISEASE; NONHUMAN; PARESTHESIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT FAILURE; VIROLOGY; VIRUS LOAD;

ADULT; CARBAMATES; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PHOSPHORIC ACID ESTERS; RITONAVIR; SALVAGE THERAPY; SULFONAMIDES; TREATMENT FAILURE; VIRAL LOAD;

EID: 25144508120     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/MV8B-2YBD-GAM7-PTXX     Document Type: Article

References (31)

1. Pallela FJ Jr, Delaney MK, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. Outpatients Study Investigators. New Engl J Med. 1998;338:853-860.
2. Mocroft A, Vella S, Benfield T, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet. 1998;352:1725-1730.
3. US Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents, March 23, 2004. Available at: http://www.AIDSinfo.nih.gov. Accessed September 4, 2004.
4. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for HIV infection. 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004;292:251-265.
5. Garcia L, Heneine W. Resistance of HIV-1 to reverse transcriptase and protease inhibitors: genotypic testing. J Clin Virol. 2001:197-212.
6. Deeks SG. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet. 2003;362:2002-2011.
7. Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmaco enhancement. HIV Med. 2001;2:105-113.
8. Sadler BM, Piliero PJ, Preston SL, Lloyd PP, Lou Y, Stein DS. Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers. AIDS. 2001;15:1009-1018.
9. Goujard C, Vincent I, Meynard JL, et al. Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother. 2003;47:118-123.
10. Wood R, Arasteh K, Stellbrink HJ, et al. Six-week randomized contolled trial to compare the tolerabilities, pharmacokinetics and antiviral activities of GW433908 and amprenavir in human-immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother. 2004;48:116-123.
11. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. New Engl J Med. 2002;346:2039-2046.
12. Kemper CA, Wit MD, Keiser PH, et al. Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors. AIDS. 2001;15:609-615.
13. Arvieux C, Tattevin P, Souala FM. et al. Salvage therapy with amprenavir and ritonavir: prospective study in 17 heavily pretreated patients. HIV Clin Trials. 2002;3:125-132.
14. Bogner JR, Eberle J, Trendle U, Goebel D. Amprenavir in pre-treated patients: virological and immunological response in a cohort of 45 patients. Eur J Med Res. 2003; 8:49-55.
15. Clevenbergh P, Boulme R, Kirstetter M, Dellamonica P. Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients. HIV Med. 2004:5;284-288.
16. Marcelin A, Lamotte C, Delaugerre C, et al. Genotypic inhibitory quotient as a predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2003;47:594-600.
17. Duval X, Lamotte C, Race E, et al. Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir. Antimicrob Agents Chemother. 2002;46:570-574.
18. DeJesus E, LaMarca A, Sension M, Beltran C, Yéni P. The Context Study: efficacy and safety of GW433908/RTV in PI-experienced subjects with virological failure (24 week results). In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston. Abstract 178.
19. Genotypic testing algorithm of French ANRS AC11 guidelines, 2003. Available at: http://www.hivfrenchresistance. org. Accessed September 2, 2004.
20. Sale M, Sadler BM, Stein DS. Pharmacokinetic modeling and simulaions of interaction of amprenavir and ritonavir. Antimicrob Agents Chemother. 2002;46:746-754.
21. Race R, Dam E, Obry V, Paulous S, Clavel F. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombination virus assay for patients failing on combination therapies. AIDS. 1999;13:2061-2068.
22. Tisdale M, Myers R, Randall S, et al. Resistance to the HIV protease inhibitor amprenavir in vitro and in clinical studies: a review. Clin Drug Invest. 2000;20:267-285.
23. Schmidt B, Korn K, Moschik B, et al. Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors. Antimicrob Agents Chemother. 2000;44(11):3213-3216.
24. Paulsen D, Liao Q, Fusco G, StClair M, Shaefer M, Ross L. Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia. AIDS Res Hum Retroviruses. 2002;18:1011-1019.
25. Paulsen D, Elston R, Snowden W, Tisdale M, Ross L. Differentiation of genotype resistance profiles for amprenavir and lopinavir, a valuable aid for choice of therapy in protease inhibitor-experienced HIV-1-infected subjects. J Antimicrob Chemother. 2003;52:319-323.
26. Falcoz C, Jenkins JM, Bye C, et al. Pharmacokintics of GW433908, a prodrug of amprenavir, in healthy male volunteers. J Clin Pharmacol. 2002;42:887-898.
27. Pulido F, Katlama C, Marquez M, et al. A randomized study investigating the efficacy and safety of amprenavir in combination with low-dose ritonavir in protease inhibitor-experienced HIV-infected adults. HIV Med. 2004:5;296-302.
28. The PLATO collaboration. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet. 2004;364:51-62.
29. Raffanti S, Fusco J, D'Aquila R, et al. Effect of persistent moderate viremia on disease progression during HIV therapy. J Acquir Immune Defic Syndr. 2004;37:1147-1154.
30. Pedneault L, Brothers C, Pagano G, Tymkewycz P, Yei J, Millard J, Fetter A. Safety profile and tolerability of amprenavir in the treatment of adult and pediatric patients with HIV infection. Clin Ther. 2000;22:1378-1394.
31. International AIDS Society Table, 2003. Available at: http://www.iasusa.org/resistancemutations/index.htlm. Accessed September 2, 2004.